Novartis

In keeping with our ambition to harness AI to accelerate the pace of drug discovery and development, Novartis has entered into a collaboration with Generate:Biomedicines. The agreement will bring together Generate’s proprietary generative AI platform and Novartis expertise and capabilities in target biology, biologics development, clinical development and more, with the goal of advancing novel biologic therapeutics for patients. https://lnkd.in/g_sRjesH

The global community has averted 11 million malaria deaths during the past two decades. But now we’ve stalled. Today, we face a perfect storm of emerging challenges ranging from climate change to early signs of drug resistance (AMR). If we take our foot off the gas pedal, we risk a malaria resurgence with a devastating toll. Let’s come together to finally outsmart malaria. It’s our responsibility. https://lnkd.in/gBycDfd6 #UNGA79 #Malaria #AMR

Novartis has been recognized as one of the World’s Best Companies in 2024 by TIME and Statista. This acknowledges our commitment to environmental, social and governance (ESG) principles, performance and employee satisfaction, and comes just a month after we were ranked in the top 20 of TIME and Statista's World's Most Sustainable Companies 2024 list. These achievements would not have been possible without our 75,000 associates, whose dedication to reimagining medicine creates sustainable impact every day. Thank you all! #ReimaginingMedicine #ESG #Sustainability

Cancer is a heterogeneous disease that approximately 1 in 5 people will develop in their lifetime. At Novartis, we are driven by a commitment to keep patients at the center while we innovate and investigate solutions that could advance cancer care. Our goal is simple: to enhance outcomes and quality of life (#QoL) for patients worldwide. Learn more about our innovative approach to cancer care: https://lnkd.in/gYrHBbSy

Bringing radioligand therapy (#RLT) to patients hinges on the readiness of our healthcare systems (HCS). We need: • Access to and availability of diagnostic equipment • Streamlined patient referral processes • More RLT centers • Robust regulatory frameworks • A skilled workforce Only by strengthening these areas can we meet the rising demand for RLT, providing eligible patients the right RLT at the right time to improve outcomes and quality of life (#QoL). Learn more about the potential of RLT to become a new pillar of cancer care: https://lnkd.in/gGC254dP

Earlier today, our CEO Vas Narasimhan joined CNBC to talk about this week’s news from the FDA and what it means for #earlybreastcancer patients with Karen Tso and Stephen Sedgwick. Vas also shared his thoughts on our work to reimagine medicine, including investments in cutting-edge cancer treatments like radioligand therapy, how we can reduce costs in the health care system, and our transition into an innovative medicines company over the past six years. It was an exciting day for our team, but what’s even more important is the impact this news will have on patients: tens of thousands of Americans who suffer from early-stage breast cancer will now be able to access treatment that reduces the likelihood of their cancer recurring. We're excited to see how access to these treatments will improve and extend patients’ lives.

Today’s FDA approval marks a pivotal achievement in our ongoing collaboration with patients, advocates, medical professionals and researchers to help address concerns around disease recurrence in #earlybreastcancer. As we celebrate this new milestone in our 35-year long journey to address the needs of people touched by breast cancer, we reflect on the personal and collective drivers behind our work in this space. Take a look at our sources of inspiration and share with us: what fuels your efforts in #breastcancer? #bcsm #ReimaginingMedicine, together

At Novartis, we are committed to raising awareness of the challenges of living with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH). This #PNHAwarenessWeek and beyond, we proudly highlight the work of the Aplastic Anemia & MDS International Foundation and their efforts. Learn more about their mission to support patients living with the disease and improve their quality of life. https://lnkd.in/gZSmTg3t

Radioligand therapy (#RLT) could be a true paradigm shift in oncology, a potential new pillar of cancer care. However, healthcare system (HCS) readiness for widespread adoption of RLT is behind the speed of innovation. Novartis is partnering with industry and regional HCSs to build capacity for RLT, supporting policies and accelerating referral and funding pathways. Join us at #ESMO2024 where we are leading a panel discussion with industry experts to discuss how we can work together to shape a future where patients with advanced cancers can live better.

Cancer is a heterogeneous disease with nearly 20 million people diagnosed in 2022 alone. At Novartis, we are on a mission to develop innovative therapies that improve the future of cancer care. Our broad oncology portfolio addresses pressing unmet needs in a range of advanced cancers, aiming to improve outcomes and enhance quality of life (#QoL) for patients and their loved ones. Learn more about our ongoing efforts in oncology: https://lnkd.in/ggv5umCv